Title: Longitudinal symptom transitions predict incident tuberculosis risk among persons deprived of liberty in Brazil

Authors: Jung, Esther* (1), Bampi, José Victor Bortolotto (2), da Silva, Alessandra Moura (2), Liu, Yiran E. (1,3,4), Tsuha, Daniel Henrique (2), Salindri, Argita D. (1), Santos, Andrea da Silva (5), de Oliveira, Roberto Dias (5,6), Croda, Julio (2,7,8), Andrews, Jason R. (1)

*Corresponding Author: Esther Jung
Stanford University School of Medicine, 240 Pasteur Dr, Stanford, CA 94304-1049
esthjung@stanford.edu, (858)260-8377

Affiliations:
1. Stanford University School of Medicine, Stanford, California
2. Federal University of Mato Grosso do Sul, Campo Grande, Brazil
3. Yale University School of Medicine, New Haven, Connecticut
4. Yale Law School, New Haven, Connecticut
5. Federal University of Grande Dourados, Dourados, Brazil
6. State University of Mato Grosso do Sul, Dourados, Brazil
7. Oswaldo Cruz Foundation, Campo Grande, Brazil
8. Yale University School of Public Health, New Haven, Connecticut

Keywords: tuberculosis; asymptomatic; prisons; active case finding; screening

ABSTRACT (100 words)

Tuberculosis (TB) screening often relies on cross-sectional symptom assessment. To determine the added value of longitudinal symptom monitoring, we conducted a prospective cohort study among 2,282 incarcerated men in Brazil without TB. Every four months, participants were assessed for symptoms and incident TB (Xpert or culture positive). At baseline, 23% of participants reported symptoms. Among those asymptomatic at baseline, 43% developed symptoms within two years. Compared to remaining asymptomatic, developing symptoms was associated with higher TB risk, while remaining symptomatic was not associated. Longitudinal symptom monitoring may provide value beyond cross-sectional symptom assessment and enhance TB screening in high-risk settings.

BACKGROUND

Tuberculosis (TB) continues to pose a major global health challenge[1]. Early detection and treatment are essential to interrupt transmission and improve outcomes, particularly in high-risk populations. Efforts to identify individuals living with TB often leverage symptom screening to prioritize individuals for confirmatory molecular rapid diagnostic tests[2]. However, conventional approaches to TB screening typically only assess symptoms present at the time of screening entry, which may not capture the dynamic nature of symptom changes during TB disease progression[3,4].

Symptoms that are typically classified as features of TB[5], such as cough, fever, night sweats, and weight loss, can fluctuate over the course of disease[6]. In high-risk populations such as persons deprived of liberty (PDL), these symptoms may also be caused by other common conditions, including upper respiratory tract infections, pneumonia, chronic obstructive lung disease and tobacco smoking[7]. Moreover, recent studies reveal that over 50% of individuals living with undiagnosed TB do not report symptoms at the time of diagnosis[1,8]. Together, the non-specific presentation of TB and high prevalence of asymptomatic TB may limit the ability of cross-sectional symptom screening to reliably identify individuals at imminent risk of active TB, resulting in continued transmission[8,9].

Longitudinal monitoring of symptoms offers an opportunity to overcome some of these challenges by capturing individuals' changes in symptom status over time, including new onset, persistence, or resolution. This may provide additional predictive value for

disease, improve identification of individuals at high risk of TB, or indicate higher risk for future evaluations, thereby facilitating the prioritization of confirmatory diagnostic testing.

Prisons harbor some of the highest TB incidence and transmission rates worldwide[10–12], and the World Health Organization recommends systematic screening be performed among incarcerated populations at least yearly[2]. However, active case finding is not widely implemented in most prisons in high-burden countries, partly due to resource constraints. Understanding how TB symptoms evolve in such settings could inform more resource-efficient screening approaches, yet longitudinal symptom trajectories in high-risk populations remain uncharacterized.

To address this knowledge gap, we characterized longitudinal symptom trajectories in a cohort of incarcerated individuals who were evaluated for TB symptoms and tested for TB every four months. We assessed the relationship between symptom transitions and risk of incident TB.

METHODS

We performed systematic screening for TB every four months from February 2023 to September 2025 in two all-male prisons in the Brazilian state of Mato Grosso do Sul. After providing informed consent to participate, participants completed a standardized symptom questionnaire, administered by study nurses, to ascertain the presence of cough, fever, night sweats, weight loss, chest pain, or dyspnea. Presence of each

symptom at each visit was assessed through yes/no questions (i.e. “Do you have a cough?”). An individual was considered symptomatic if they confirmed the presence of any of these symptoms.

At baseline, all consenting participants, regardless of symptoms, had a posterior-anterior chest radiograph performed and two sputum samples collected for testing by culture and Xpert® MTB/RIF Ultra (hereinafter “Xpert”). Chest radiographs were evaluated using automated detection software LunitTB (South Korea; version v3.1.5.1), which outputs a numerical TB risk score on a continuous scale between 0 and 100.

At each four-month follow-up visit, procedures were repeated: symptom assessment, a single sputum sample collection, and chest radiography. Symptom status transitions over sequential four-month intervals were categorized as asymptomatic-to-symptomatic, symptomatic-to-asymptomatic, persistently symptomatic, or persistently asymptomatic. Incident TB was defined by at least one positive sputum culture or Xpert result.

Eligibility was restricted to those with negative baseline Xpert and culture results at baseline to ensure participants did not have prevalent TB. Only participants who completed at least one follow-up visit during the study period were included, to permit longitudinal assessment of symptom status and incident TB.

Given the frequent transfers and movement within the prison system, nearly 25% of individuals enrolled in the cohort missed follow-up visits intermittently. We excluded

individuals with non-consecutive symptom information, as gaps in reporting precluded reliable classification of symptom transitions across sequential four-month intervals into the predefined symptom trajectory categories.

We used the chi-square and Kruskal-Wallis tests to compare baseline demographic and clinical characteristics across symptom transition groups in the first four-month interval.

In supplementary analyses, we evaluated all four-month symptom transitions across the study period to identify predictors associated with developing or resolving symptoms. We performed modified Poisson regression with robust standard errors clustered at the individual level to estimate adjusted risk ratios (aRRs)[13]. Models adjusted for the following covariates: age, prison, prior TB, exposure to symptomatic cellmates (yes/no), TB contact (ever/never), current smoking status, any drug use, duration of incarceration, and binary LunitTB x-ray score using a threshold of 50 as a proxy for baseline lung abnormalities. Separate models were constructed for individuals who were asymptomatic at the prior visit (assessing the risk of becoming symptomatic) and for those who were symptomatic at the prior visit (assessing the risk of becoming asymptomatic).

Specific symptom-level transition patterns were summarized descriptively by calculating the proportion of each individual TB-related symptom reported at visits where a

transition occurred, distinguishing between new onset, resolution, and persistent symptoms.

We also characterized how long participants remained in their initial symptom state during follow-up using survival analysis. For symptomatic individuals, the event was the first resolution of symptoms, while for asymptomatic individuals, the event was the first acquisition of symptoms. Participants were censored at TB diagnosis, loss to follow-up, or last study visit.

For the primary analysis, we assessed whether symptom transitions during the preceding four-month interval were associated with incident TB diagnosed at the subsequent visit, using the same modified Poisson framework described above. Persistently asymptomatic individuals served as the reference category. All analyses were conducted in R (version 4.4.1).

Ethical approval was obtained from the Research Ethics Committee of the Federal University of Mato Grosso do Sul, the Brazilian National Commission for Ethics in Research, and the Stanford University Research Ethics Committee.

RESULTS

147 After applying inclusion criteria, our study identified 2,282 participants without TB at
148 baseline who were assessed for symptoms at two or more consecutive visits between
149 February 2023 and September 2025. The median baseline age of participants was 33
150 years (IQR 28-40), over 80% of participants were Black or mixed race (1,854/2,282),
151 and most participants did not complete high school (83%) (Table 1).

152

153 The majority of individuals reported no TB symptoms at baseline (1,747/2,282, 76.5%)
154 and 62.1% (1,417/2,282) remained asymptomatic at the first follow-up. Notably, 57%
155 (35/61) of incident TB cases occurred among participants who remained asymptomatic.
156 Among those asymptomatic at baseline, 14.5% developed symptoms by the first follow-
157 up. Of the 23.4% symptomatic at baseline, 40% remained symptomatic and 60%
158 reported resolution (Table 1). Several characteristics differed significantly across
159 transition groups, with individuals with persistent symptoms showing the highest
160 prevalence of these factors: previous TB (25.1%), exposure to symptomatic cellmates
161 (61.4%), current smoking (76.7%), and any drug use (69.8%) (Table 1).

162

163 Among participants symptomatic at baseline (n = 535), the probability of remaining
164 symptomatic declined steeply to 40.2% at the first follow-up, 19.3% at the second, and
165 7.6% by the last visit. In contrast, symptom absence was more stable: among those
166 asymptomatic at baseline (n = 1,749), 81.1% remained asymptomatic at the first follow-
167 up and 43.8% were still asymptomatic at the last visit (Supplementary Figure 1).

168

169 Symptom-level transitions revealed that cough (with or without sputum production) was
170 the most frequently reported symptom among those developing symptoms (66%) and
171 among those resolving symptoms (68%). Other common symptoms associated with
172 symptom changes included chest pain, breathing difficulty, weight loss, and fever
173 (Supplementary Figure 2).

174

175 When evaluating predictors for symptom transitions longitudinally among previously
176 asymptomatic individuals, the onset of any TB symptom within the subsequent four-
177 month interval was associated with a previous TB diagnosis (aRR 1.26; 95% CI 1.08-
178 1.47; $p = 0.004$), current smoking (aRR 1.81; 95% CI 1.53-2.15; $p < 0.001$), past
179 smoking (aRR 1.34; 95% CI 1.09-1.66; $p = 0.005$), any drug use (aRR 1.23; 95% CI
180 1.08-1.41; $p = 0.002$), and exposure to symptomatic cellmates (aRR 1.30; 95% CI 1.15-
181 1.47; $p < 0.001$). Among previously symptomatic individuals, resolution of symptoms
182 was less likely among those who reported current smoking (aRR 0.82; 95% CI 0.72-
183 0.92; $p = 0.001$) or any drug use (aRR 0.88; 95% CI 0.79-0.97; $p = 0.010$)
184 (Supplementary Table 1). In interaction models, these predictors did not significantly
185 modify the association between symptom transitions and TB risk.

186

187 Longitudinal analyses showed that compared to persistently asymptomatic individuals,
188 transitioning from an asymptomatic to a symptomatic state within a four-month interval
189 was significantly associated with incident TB (aRR 2.11; 95% CI 1.45-3.07). In contrast,

190 remaining symptomatic (aRR 1.05; 95% CI 0.60-1.85) or resolution from symptomatic to
191 asymptomatic (aRR 1.02; 95% CI 0.61-1.68) were not significantly associated with TB
192 risk, compared to those who stayed persistently asymptomatic (Figure 1).

193

194 **DISCUSSION**

195 In our longitudinal cohort study in two high-incidence prisons, we found that TB-related
196 symptoms followed dynamic trajectories over four-month intervals. Between enrollment
197 and the first follow-up visit just four months later, nearly one in seven (14.5%)
198 developed new symptoms, and 60% of those symptomatic at baseline reported
199 resolution, underscoring the fluctuating nature of TB-related symptom reporting in this
200 population. These observations align with a recent systematic review describing the
201 natural history of pulmonary TB as heterogeneous trajectories with frequent movement
202 between symptom states, rather than a linear progression to disease[14].

203

204 Importantly, more than half of all incident TB cases (57%, 35/61) occurred among
205 participants who remained asymptomatic at both visits, highlighting the substantial
206 limitations of symptom-based screening in this setting. Prior studies in prisons and other
207 high-risk congregate settings have similarly documented that reliance on symptom-
208 based screening alone misses a considerable fraction of active TB cases, supporting
209 the need for repeated active case-finding[4,15]. Together, these findings underscore that
210 cross-sectional symptom screening alone fails to capture a large proportion of active
211 TB. Although our study was not designed to assess the additional yield of repeated
212 symptom assessments, longitudinal monitoring may provide value in understanding

213 disease progression, particularly when combined with complementary strategies such
214 as routine sputum testing or radiographic evaluation.
215
216 Specifically, our analyses demonstrate that participants who developed new symptoms
217 had more than double the risk of TB diagnosis compared to those who remained
218 asymptomatic, while persistent symptoms conferred no excess risk. This pattern
219 suggests that symptom emergence, rather than chronic symptom presence, offers
220 greater resolution for identifying short-term risk. This may reflect the high sensitivity of
221 our combined diagnostic strategy, which likely detected new TB cases rapidly, leaving
222 few recent-onset cases undiagnosed. In contrast, participants with persistent symptoms
223 may have alternative or unresolved etiologies, such as concomitant respiratory
224 infections, which could obscure the relationship with incident TB.
225
226 We also identified key factors associated with four-month symptom transitions. Among
227 previously asymptomatic individuals, previous TB, current and past smoking, and
228 exposure to symptomatic cellmates increased the risk of developing symptoms. In
229 contrast, current smoking and drug use were associated with persistent symptoms.
230 While these predictors shaped symptom trajectories, they did not significantly modify
231 the primary association between transitions and TB risk in interaction models.
232 Nonetheless, combining repeated symptom assessments with knowledge of exposure-
233 related risk factors may allow public health programs to more precisely target diagnostic
234 interventions toward those at highest short-term TB risk.
235

Our study had several limitations. Symptom reporting relied entirely on self-report, which may be influenced by recall bias. Additionally, the four-month interval between screenings may not have captured shorter-term or transient symptom fluctuations. Excluding participants with intermittently missing visits may have introduced bias by removing those with less stable follow-up due to transfer or refusal. Despite these limitations, our findings offer important insights into the temporal dynamics of TB symptoms and their potential utility in prioritizing individuals at highest risk for diagnostic screening and treatment.

In conclusion, longitudinal assessment of TB-related symptoms reveals dynamic patterns of emergence and resolution that identify individuals at elevated short-term risk of active disease. Our findings suggest that symptom trajectory monitoring can complement existing tools to strengthen case detection. Algorithms prioritizing individuals with either new-onset symptoms or radiographic abnormalities for molecular testing may improve sensitivity and cost-effectiveness in high-transmission, resource-limited settings. Future studies should assess how integrating longitudinal symptom monitoring, radiography, and rapid diagnostics can be operationalized to optimize detection and reduce transmission.

Acknowledgements EJ, JRA, and JC conceived of the study. JRA, JC, and RDO developed the study plans. AmdS and AdSS enrolled participants and collected data. DHT performed data management. EJ, JVBB, YL, ADS, and JRA designed and performed the data analysis. EJ and JVBB wrote the manuscript. All authors contributed to revising the manuscript.

The authors acknowledge the use of ChatGPT (GPT-4, OpenAI) for troubleshooting coding errors and minor grammar checking. AI was not used for generation of conclusions or interpretation of results. All content and analyses were independently verified by the authors, who take full responsibility for the manuscript.

Funding This work was supported by Brazil's Ministry of Health; Brazil's National Council for Scientific and Technological Development [CNPq; 404182/2019-4 to JC] and the U.S. National Institutes of Health [R01AI130058, K24AI182647 to JRA].

Conflicts of interest The authors do not declare any conflicts of interests in preparing this article.

Data availability Analytic code is available at https://github.com/Andrews-Lab-Stanford/LongitudinalTBSymptoms_BrazilPrisons.git

274 **Table 1.** Characteristics of participants by symptom transition between baseline and

275 first follow-up visit (N = 2,282)

Characteristics	Overall (N = 2,282)	First 4-month interval symptom transition				p-value*
		Persistently asymptomatic (n = 1,417)	Persistently symptomatic (n = 215)	Asymptomatic to Symptomatic (n = 330)	Symptomatic to Asymptomatic (n = 320)	
Median age (IQR)	33 (28, 40)	33 (28, 40)	33 (28, 40)	32 (27, 39)	33 (27, 40)	0.208
Incident TB	61 (2.7)	35 (2.5)	17 (5.2)	5 (1.6)	4 (1.9)	0.018
Ethnicity						0.204
White	419 (18.4)	251 (17.7)	40 (18.6)	57 (17.3)	71 (22.2)	
Black	217 (9.5)	127 (8.9)	27 (12.6)	33 (10.0)	30 (9.4)	
Mixed	1,637 (71.7)	1,034 (73.0)	145 (67.4)	239 (72.4)	219 (68.4)	
Asian	8 (0.4)	4 (0.3)	3 (1.4)	1 (0.3)	0 (0)	
Indigenous	1 (<0.1)	1 (<0.1)	0 (0)	0 (0)	0 (0)	
Education						0.562
Less than high school	1,893 (83.0)	1,175 (82.9)	181 (84.2)	279 (84.5)	258 (80.6)	
Completed high school	389 (17.0)	242 (17.1)	34 (15.8)	51 (15.5)	62 (19.4)	
Prison						0.256
EPJFC	1,745 (76.5)	1,089 (76.9)	165 (76.7)	239 (72.4)	252 (78.8)	
IPCG	537 (23.5)	328 (23.1)	50 (23.3)	91 (27.8)	68 (21.3)	
Previous TB	409 (17.9)	225 (15.9)	54 (25.1)	67 (20.3)	63 (19.7)	0.004
TB contact	1,335 (58.5)	818 (57.7)	135 (62.8)	204 (61.8)	178 (55.6)	0.239
Symptomatic cellmates	854 (37.4)	415 (29.3)	132 (61.4)	126 (38.2)	181 (56.6)	<0.001
Current smoking	1,342 (58.8)	741 (52.3)	165 (76.7)	220 (66.7)	216 (67.5)	<0.001
Any drug use	1,416 (62.1)	829 (58.5)	150 (69.8)	226 (68.5)	211 (65.9)	<0.001
LunitTB Score at Baseline						0.961
<50	1,584 (69.4)	984 (69.4)	146 (67.9)	230 (69.7)	224 (70.0)	
≥50	698 (30.6)	433 (30.6)	69 (32.1)	100 (30.3)	96 (30.0)	
Months incarcerated, median (IQR)	12 (2, 44)	13 (2, 41)	14 (2, 71)	11 (2, 34)	9 (1, 61)	0.213

276 No (% of column n) unless otherwise specified.

277 *Pearson's Chi-squared test; Kruskal-Wallis test

278

279 **Figure 1**. Adjusted risk of incident TB by symptom transitions over four-month intervals

280



281

282 Adjusted risk ratios (aRRs) represent adjusted risk of TB diagnosed by sputum culture or Xpert within the same four-month interval as the symptom
283 transition. Models adjust for baseline characteristics including age, prison, prior TB, smoking, drug use, duration of incarceration, symptomatic cellmates,
284 TB contact, and Lunit x-ray score.

285 **Alt text:** Forest plot showing adjusted risk of incident tuberculosis by symptom transitions over four-month intervals. Compared with participants who
286 remained asymptomatic, those who became symptomatic had over twice the risk of TB. Risks for persistent or resolving symptoms were similar to the
287 reference group.

288

289

290 **REFERENCES**

291 1. World Health Organization. Global Tuberculosis Report 2024.
292 https://www.who.int/teams/global-programme-on-tuberculosis-and-lung-health/tb-
293 reports/global-tuberculosis-report-2024 (2024).
294 2. World Health Organization. *WHO Consolidated Guidelines on Tuberculosis. Module*
295 *2: Screening - Systematic Screening for Tuberculosis Disease*. (2021).
296 3. Kendall, E. A., Shrestha, S. & Dowdy, D. W. The Epidemiological Importance of
297 Subclinical Tuberculosis. A Critical Reappraisal. *Am. J. Respir. Crit. Care Med.* **203**,
298 168–174 (2021).
299 4. Yoon, C., Dowdy, D. W., Esmail, H., MacPherson, P. & Schumacher, S. G.
300 Screening for tuberculosis: time to move beyond symptoms. *Lancet Respir. Med.* **7**,
301 202–204 (2019).
302 5. CDC. Clinical Symptoms of Tuberculosis. *Tuberculosis (TB)*
303 https://www.cdc.gov/tb/hcp/clinical-signs-and-symptoms/index.html (2024).
304 6. Richards, A. S. *et al.* Quantifying progression and regression across the spectrum of
305 pulmonary tuberculosis: a data synthesis study. *Lancet Glob. Health* **11**, e684–e692
306 (2023).
307 7. Viglianti, E. M., Iwashyna, T. J. & Winkelman, T. N. A. Mass Incarceration and
308 Pulmonary Health: Guidance for Clinicians. *Ann. Am. Thorac. Soc.* **15**, 409–412
309 (2018).
310 8. Emery, J. C. *et al.* Estimating the contribution of subclinical tuberculosis disease to
311 transmission: An individual patient data analysis from prevalence surveys. *eLife* **12**,
312 e82469 (2023).

313 9. da Silva Peres Bezerra, W. *et al.* The role of tuberculosis symptoms in transmission
314 risk to cell contacts in prisons. *MedRxiv Prepr. Serv. Health Sci.*
315 2025.05.27.25328413 (2025) doi:10.1101/2025.05.27.25328413.
316 10. Martinez, L. *et al.* Global, regional, and national estimates of tuberculosis incidence
317 and case detection among incarcerated individuals from 2000 to 2019: a systematic
318 analysis. *Lancet Public Health* **8**, e511–e519 (2023).
319 11. Walter, K. S. *et al.* The escalating tuberculosis crisis in central and South American
320 prisons. *Lancet Lond. Engl.* **397**, 1591–1596 (2021).
321 12. Cords, O. *et al.* Incidence and prevalence of tuberculosis in incarcerated
322 populations: a systematic review and meta-analysis. *Lancet Public Health* **6**, e300–
323 e308 (2021).
324 13. Zou, G. A Modified Poisson Regression Approach to Prospective Studies with
325 Binary Data. *Am. J. Epidemiol.* **159**, 702–706 (2004).
326 14. Sossen, B. *et al.* The natural history of untreated pulmonary tuberculosis in adults: a
327 systematic review and meta-analysis. *Lancet Respir. Med.* **11**, 367–379 (2023).
328 15. Bailey, S. L. *et al.* Missed opportunities for tuberculosis diagnosis. *Int. J. Tuberc.*
329 *Lung Dis. Off. J. Int. Union Tuberc. Lung Dis.* **15**, 205–i (2011).
330

APPENDIX

Supplementary Figure 1. Symptom persistence by baseline symptom status



Visit number	V0	V1	V2	V3	V4	V5	V6
n remaining asymptomatic	1747	1417	980	699	512	391	230

Visit number	V0	V1	V2	V3	V4	V5	V6
n remaining symptomatic	535	215	68	26	19	10	4

Risk tables with raw numbers of participants at each visit are shown beneath the curves.

Alt text: Kaplan-Meier curves showing symptom persistence by baseline symptom status. Participants starting asymptomatic had a gradual decline in remaining asymptomatic, while those starting symptomatic showed rapid symptom resolution over follow-up visits.

Supplementary Figure 2. Specific symptom changes by symptom transition group



% of total instances of symptom transition in that symptom category. Symptom changes refer to new onset (Asymptomatic to Symptomatic group), resolution (Symptomatic to Asymptomatic), or either (Symptomatic to Symptomatic).

Alt text: Heatmap showing percentage changes in specific symptoms by symptom transition group. Color intensity reflects percent change, highest among transitions involving cough-related symptoms.

344

345 **Supplementary Table 1**. Predictors of symptom change stratified by prior symptom status

346 Previously asymptomatic

Predictors	Becoming symptomatic		
	aRR*	95% CI	p-value
Previous TB	1.26	(1.08-1.47)	0.004
Current smoking	1.81	(1.53-2.15)	<0.001
Past smoking	1.34	(1.09-1.66)	0.005
Any drug use	1.23	(1.08-1.41)	0.002
Symptomatic cellmates	1.30	(1.15-1.47)	<0.001
TB contact	1.03	(0.91-1.17)	0.662
LunitTB ≥50	0.90	(0.78-1.04)	0.164

347

348 Previously symptomatic

Predictors	Becoming asymptomatic		
	aRR*	95% CI	p-value
Previous TB	0.94	(0.83-1.06)	0.340
Current smoking	0.82	(0.72-0.92)	0.001
Past smoking	0.96	(0.83-1.10)	0.563
Any drug use	0.88	(0.79-0.97)	0.010
Symptomatic cellmates	0.92	(0.84-1.00)	0.057
TB contact	0.92	(0.84-1.01)	0.077
LunitTB ≥50	0.98	(0.88-1.10)	0.784

349 *Adjusted risk ratios (aRRs) represent risk of symptom status change from prior status compared to no change in symptom status. Multivariate logistic regression
350 models with cluster-robust standard errors at the individual level to estimate odds of symptom transitions, adjusting for baseline characteristics including age,
351 prison, prior TB, smoking, drug use, prison time, symptomatic cellmates, TB contact, and categorical LunitTB x-ray score.

352